Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques

Journal of Infectious Diseases

Volumn 186, Issue 10, 2002, Pages 1469-1473

  Fong, Ignatius W ^a   Chiu, Brian ^c   Viira, Esther ^a   Tucker, William ^a   Wood, Heidi ^b   Peeling, Rosanna W ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; C REACTIVE PROTEIN; HEAT SHOCK PROTEIN 60;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BACTERIUM IDENTIFICATION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIBODIES; ANTIGENS, BACTERIAL; ARTERIOSCLEROSIS; CHAPERONIN 60; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; STATISTICS;

EID: 0037111089     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344730     Document Type: Article

References (52)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340:115-26.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331:468-9.
3. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest 1988; 58:249-61.
4. Saikku P, Leinonen M, Matilla K, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2:983-6.
5. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350:430-6.
6. Ossewaarde JM, Feskers EJ, De Vries A, Vallinga LE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120:93-9.
7. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999; 30:299-305.
8. Strachan DP, Carrington D, Mendall MA, et al. Relationship of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart study. BMJ 1999; 318:1035-40.
9. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150:1785-90.
10. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96:2144-8.
11. Taylor-Robinson D. Chlamydia pneumoniae in vascular tissue. Atherosclerosis 1998; 140 (Suppl 1):S21-4.
12. Shot A, Phillips JI, Ong G. Thomas BJ, Taylor-Robinson D. Chlamydia pneumoniae in atheroma: Consideration of criteria for causality. J Clin Pathol 1998; 51:812-7.
13. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Chlamydia pneumoniae/atherosclerosis Study Group. Ann Intern Med 1996; 125:979-82.
14. Jackson LA, Campbell LA, Kuo CC, Rodriguez DL, Lee A, Grayston JT.Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176:292-5.
15. Maas M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31:827-32.
16. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and the treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-6.
17. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999; 67:6048-55.
18. Moazed TC, Campbell LA, Rosenfield ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in alipoprotein E-deficient mice. J Infect Dis 1999; 180:238-41.
19. Hu H, Pierce GN, Zhang G. Atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103:747-53.
20. Kol A. Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein-60 localizes in human atheroma and regulates macrophage tumour necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98:300-7.
21. Claman P, Honey L, Peeling RW, Jessamine P, Toye B. The presence of serum antibody to chlamydial heat shock protein (CHSP 60) as a diagnostic test for tubal factor infertility. Fert Steril 1997; 67:501-4.
22. Eckert LO, Hawes SE, Wolner-Hanssen P, et al. Prevalence and correlates of antibody to chlamydial heart shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. J Infect Dis 1977; 175:1453-8.
23. Toye B, Laferriere C, Claman P, Jessamine P, Peeling R. Association between antibody to the chlamydial heat shock protein and tubal infertility. J Infect Dis 1993; 168:1236-40.
24. Domeika M, Domeika K. Paavonen J. Mardh PA, Wilkin SS. Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat shock protein in women with pelvic inflammatory disease. J Infect Dis 1998; 177:714-9.
25. Dieterle S. Wollenhaupt J. Humoral immune response to the chlamydial heat shock proteins hsp-60 and hsp-70 in chlamydia-associated chronic salpingitis with tubal occlusion. Human Reprod 1996; 11:1352-6.
26. Witkin SS, Jeremias J, Toth M, Ledger WJ. Proliferative response to conserved epitopes of Chlamydia trachomatis and human 60 kilodalton heat shock proteins by lymphocytes from women with salpingitis. Am J Obstet Gyne 1994; 171:455-60.
27. Eda S, Kaufman J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Analysis 1998; 12:137-44.
28. Wang S. Serology for Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F. eds. Chlamydia Pneumoniae: The Lung and the Heart. Milan: Springer-Verlag, 1999.
29. Danesh J, Collins R, Appleby P. Peto R. Association of fibrinogen, C-reactive protein, albumen or leucocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279:1477-82.
30. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999; 30:933-7.
31. Koenig W. Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONCIA (Monitoring Trends and Determinants in Cardiovascular Disease) Angsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-42.
32. Kuller LH, Tracy RP. Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epid 1996; 144:537-47.
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97:425-8.
34. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995; 73:374-9.
35. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arteriol Thromb Vasc Biol. 2000; 20:1052-6.
36. Berger M, Schroder B, Daeschlein G, et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leucocytes. J Lab Clin Med 2000; 136:194-200.
37. Anderson JL, Muhlestein JB, Carlquist J. et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: Elimination of myocardial infarction with chlamydia (ACADEMIC) Study. Circulation 1999; 99:1538-9.
38. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infection, inflammation and the risk of coronary heart disease. Circulation 2000; 101:252-7.
39. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000; 321:199-204.
40. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 15:757-63.
41. Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34:1435-9.
42. Xu Q, Dietrich H, Steiner HJ, et al. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Atherioscler Thromb 1992; 12:789-99.
43. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity and atherosclerosis: associations of antibodies to Chlamydia pneumoniae. Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102:833-9.
44. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock protein as a possible link between infection and atherosclerosis. Circulation 1999; 99:1560-6.
45. Kol A, Boucier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells and macrophages. J Clin Invest 1999; 103:571-7.
46. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Byrne GI. Cellular oxidation of low density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180:780-90.
47. Jantos CA, Krombach C, Wuppermann FN, et al. Antibody response to the 60-kDa heat-shock protein of Chlamydia pneumoniae in patients with coronary artery disease. J Infect Dis 2000; 181:1700-5.
48. LaVerda D, Kalayoglu MV, Byrne GI. Chlamydial heat shock proteins and disease pathology: New paradigms for old problems? Infect Dis Obstet Gynecol 1999; 7:64-71.
49. Peeling RW, Mabey DCW. Heat shock protein expression and immunity in chlamydial infections. Infect Dis Obstet Gynecol 1999; 7:72-79.
50. Maas M, Gieffers J, Krause E, Engel PM, Bartels C. Solbach W. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol 1998; 187:103-6.
51. Bartels C, Maas M, Bein G, et al. Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease. Circulation 2000; 101:137-41.
52. Strong JP, Malcolm GT, McMahon CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 1999; 281:727-35.